Articles related to SOLID TUMORS

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

Understanding the nuances in diagnosing soft tissue masses is crucial for healthcare providers, as misdiagnosis can lead to delays in treatment and potentially worsen patient outcomes.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

This multinational study offers a comprehensive analysis of the association between protracted low dose exposure to ionising radiation and solid cancer mortality. Physicians and healthcare professionals may find the results significant in understanding and enhancing radiation protection, especially in contemporary medical settings.

The targeted chemotherapy pill AOH1996, developed by the City of Hope, has shown promising results in preclinical research by targeting PCNA, a protein once thought to be too challenging for targeted therapy. Explore the potential of this novel approach as it advances to phase 1 clinical trials.

Roswell Park Comprehensive Cancer Center Shines at ASCO 2023 Roswell Park Comprehensive Cancer Center recently showcased a series of groundbreaking research studies at the American Society of Clinical Research (ASCO) 2023 meeting, highlighting their commitment to advancing cancer management and clinical trials. “This study has revealed differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older CRC populations. This biology should be explored in the future, as new avenues for treatment in younger CRC populations.” Dr. Deepak Vadehra from the “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients” study